3 ms·
Sure, I'm disputing either of those claims. But if you look at it from the perspective of a drug company the existing way is fine (for now) and it's risky to sw
by jeffreyrogers 8y ago
Sure, I'm disputing either of those claims. But if you look at it from the perspective of a drug company the existing way is fine (for now) and it's risky to switch.
- jeffreyrogers 8y agoOops should have said "not disputing".